Comparison of an Ultra-low Strut Thickness Everolimus-eluting Biodegradable Polymer Stent Versus Durable Polymer Everolimus-eluting Stents in Patients Treated with Percutaneous Coronary Intervention
Recruiting now · Not applicable
Conditions studied: Ischemia, Myocardial, Coronary Artery Disease, Percutaneous Coronary Intervention (PCI)
In brief
The objective of this randomized study is to compare the safety and efficacy of the ultra-low strut thickness everolimus-eluting biodegradable polymer Evermine50 stent to the everolimus-eluting family stents (durable polymer everolimus-eluting Xience or Promus stents) in a population-based setting with coronary artery stenosis treated with percutaneous coronary intervention
Key facts
- Study ID
- NCT06692140
- Run by
- Odense University Hospital
- People needed
- 3150
- Starts
- 2024-11-16
- Expected to finish
- 2032-07-01
- Last updated by the study team
- 2024-12-09
Who can join
Age: 18 and older. Sex: any. Healthy volunteers: not accepted.
You may qualify if…
- All patients aged ≥18 years who are eligible for treatment with one or several drug-eluting coronary stents
You may not qualify if…
- Age < 18 years
- Not able to consent to study participating (eg. intubated patients)
- Unstable circuit or in cardiogenic shock and therefore not able to understand the information and purpose of the study
- Do not speak Danish
- Already included in the SORT OUT XII study
- Life expectancy <1 year
- Allergic to study related treatment
Where it is running
- Aalborg University Hospital — Aalborg, Denmark (enrolling)
- Aarhus University Hospital — Aarhus, Denmark (enrolling)
- Odense University Hospital — Odense, Denmark (enrolling)
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.